|
1
|
Rao PS, Ramanadham M and Prasad MN:
Anti-proliferative and cytotoxic effects of Strychnos
nux-vomica root extract on human multiple myeloma cell
line-RPMI 8226. Food Chem Toxicol. 47:283–288. 2008.
|
|
2
|
Spisek R, Charalambous A, Mazumder A, et
al: Bortezomib enhances dendritic cell (DC)-mediated induction of
immunity to human myeloma via exposure of cell surface heat shock
protein 90 on dying tumor cells: therapeutic implications. Blood.
109:4839–4845. 2007. View Article : Google Scholar
|
|
3
|
Arron JR and Choi Y: Bone versus immune
system. Nature. 408:535–536. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang HW, Sharp TV, Koumi A, et al:
Characterization of an anti-apoptotic glycoprotein encoded by
Kaposi’s sarcoma-associated herpesvirus which resembles a spliced
variant of human survivin. EMBO J. 21:2602–2615. 2002.PubMed/NCBI
|
|
5
|
Shen Y, Devgan G, Darnell JE Jr and
Bromberg JF: Constitutively activated Stat3 protects fibroblasts
from serum withdrawal and UV-induced apoptosis and antagonizes the
proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA.
98:1543–1548. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yuan LQ, Xie H, Luo XH, et al: Taurine
transporter is expressed in osteoblasts. Amino Acids. 31:157–163.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kanzaki H, Chiba M, Shimizu Y and Mitani
H: Dual regulation of osteoclast differentiation by periodontal
ligament cells through RANKL stimulation and OPG inhibition. J Dent
Res. 80:887–891. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khosla S: Minireview: the OPG/RANKL/RANK
system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Giuliani N, Colla S and Rizzoli V: New
insight in the mechanism of osteoclast activation and formation in
multiple myeloma: focus on the receptor activator of NF-kappaB
ligand (RANKL). Exp Hematol. 32:685–691. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giuliani N, Colla S, Morandi F,
Barille-Nion S and Rizzoli V: Lack of receptor activator of nuclear
factor-κB ligand (RANKL) expression and functional production by
human multiple myeloma cells. Haematologica. 90:275–278. 2005.
|
|
12
|
Heider U, Zavrski I, Jakob C, et al:
Expression of receptor activator of NF-κB ligand (RANKL) mRNA in
human multiple myeloma cells. J Cancer Res Clin Oncol. 130:469–474.
2004.
|
|
13
|
Jakob F, Seefried L and Ebert R:
Pathophysiology of bone metabolism. Internist (Berl). 49:1159–1160.
2008.(In German).
|
|
14
|
Anastasilakis AD, Toulis KA, Polyzos SA
and Terpos E: RANKL inhibition for the management of patients with
benign metabolic bone disorders. Expert Opin Investig Drugs.
18:1085–1102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eghbali-Fatourechi G, Khosla S, Sanyal A,
Boyle WJ, Lacey DL and Riggs BL: Role of Rank Ligand in mediating
increased bone resorption in early post-menopausal women. J Clin
Invest. 111:1221–1230. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
von Knoch F, Jaquiery C, Kowalsky M, et
al: Effects of bisphosphonates on proliferation and osteoblast
differentiation of human bone marrow stromal cells. Biomaterials.
26:6941–6949. 2005.PubMed/NCBI
|
|
17
|
Giner M, Rios MA, Montoya MA, et al:
RANKL/OPG in primary cultures of osteoblasts from post-menopausal
women. Differences between osteoporotic hip fractures and
osteoarthritis. J Steroid Biochem Mol Biol. 113:46–51. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wada N, Maeda H, Tanabe K, et al:
Periodontal ligament cells secrete the factor that inhibits
osteoclastic differentiation and function: the factor is
osteoprotegerin/osteoclastogenesis inhibitory factor. J Periodontal
Res. 36:56–63. 2001. View Article : Google Scholar
|
|
19
|
Owen TA, Aronow M, Shalhoub V, et al:
Progressive development of the rat osteoblast phenotype in vitro:
reciprocal relationships in expression of genes associated with
osteoblast proliferation and differentiation during formation of
the bone extracellular matrix. J Cell Physiol. 143:420–430. 1990.
View Article : Google Scholar
|
|
20
|
Schwartz AV, Sellmeyer DE, Vittinghoff E,
et al: Thiazolidinedione use and bone loss in older diabetic
adults. J Clin Endocrinol Metab. 91:3349–3354. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin TH, Yang RS, Tang CH, Lin CP and Fu
WM: PPARgamma inhibits osteogenesis via the down-regulation of the
expression of COX-2 and iNOS in rats. Bone. 41:562–574. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Robinson JA, Harris SA, Riggs BL and
Spelsberg TC: Estrogen regulation of human osteoblastic cell
proliferation and differentiation. Endocrinology. 138:2919–2927.
1997.PubMed/NCBI
|
